Core Scientific Inc vs Danaher Corporation — how do they compare? Core Scientific Inc trades at $15.41 (market cap $4.94B), while Danaher Corporation trades at $219.87 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 30.9× Core Scientific Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Danaher Corporation for 69 Days on average.
| CORZ | DHR | |
|---|---|---|
Market Cap | $4.94B | $152.87B |
Volume | 15,630,800 | 5,228,698 |
Sector | Technology | Health |
52-Week High | $29.16 | $242.05 |
52-Week Low | $13.57 | $161.91 |
Typical Hold Time | 20 Days | 69 Days |
Enterprise Value | $7.46B | $175.08B |
Dividend Yield | — | 0.74% |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.36, down 3.64% on the day, with bearish technical signals and negative earnings momentum. The company reported a net loss of $288.62 million in 2025 with revenue of $319.02 million, resulting in a -324.9% net income margin. Despite financial challenges, analyst sentiment remains overwhelmingly positive with 19 buy ratings and a $32.75 consensus price target, representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong Wall Street support but substantial fundamental challenges. Positive catalysts include the AI data center transition and insider buying, while risks include persistent losses, heavy capital expenditures, and competitive pressures in the digital infrastructure space.
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →